View more in
Industry

Single BioNTech/Pfizer vaccine dose reduces risk of COVID-19 by nearly 52%, matching clinical trial data

News-Medical.net
 2021-06-07

Cover picture for the articleResults from large-scale vaccinations match findings from clinical trials for the BioNTech/Pfizer messenger ribonucleic acid (mRNA) vaccine. Data gathered from real-world vaccination programs following a single dose of Pfizer vaccine administration shows a reduction of 51.4% in infection risk and effectiveness of 54.4% against symptomatic coronavirus disease 2019 (COVID-19), matching clinical trial results.

www.news-medical.net

Comments / 1

Comments / 1